Harry Glorikian

CEO, Sr. Executive, Board Director, Author, MoneyBall Medicine & Commercialization of Novel IVDs​

Harry Glorikian is an influential global business expert with more than three decades of experience building successful ventures in North America, Europe, Asia and the rest of the world. Harry is well known for achievements in life sciences, healthcare, healthcare IT and the convergence of these areas. He is a sought-after speaker, frequently quoted in the media, and regularly asked to assess, influence, and be part of innovative concepts and trends. He holds four US patents in telecommunications, and has others pending.

He recently served as an Entrepreneur In Residence to GE Ventures – New Business Creation Group. He serves on the board of GeneNews Ltd. (a molecular diagnostic company). He also serves on the advisory board of Nucelis (a gene-editing industrial biotech company), Evidation Health (a digital health startup launched with support from GE Ventures), and several other companies. He is also a co-founder and an advisory board member of DrawBridge Health (a revolutionary diagnostics startup launched with support from GE Ventures).

Previously he co-founded and held the position of managing director and head of consulting services for Scientia Advisors, a company that became the go-to provider of strategic advice and implementation services for next-generation healthcare and life science innovators and Global 25 market leaders. Scientia Advisors was acquired by Precision for Medicine in November of 2012. Among his other professional roles, Mr. Glorikian served as senior manager for global business development at PE Applied Biosystems, founded X-Cell Laboratories, managed global sales at Signet Laboratories and held various roles at BioGenex Laboratories.

Mr. Glorikian holds an MBA from Boston University and a bachelor’s degree from San Francisco State University. Harry has addressed the National Institutes of Health, Molecular Medicine Tri-Conference, World Theranostics Congress and other audiences, worldwide. He has authored numerous articles for industry publications, appeared on CBS Evening News and been quoted regularly by Dow Jones, The Boston Globe, BioWorld Today, Los Angeles Times, London Independent, Medical Device Daily, Science Magazine, Genetic Engineering News and many other media outlets. He is also the Author of two books: Commercializing Novel IVD’s; A Comprehensive Manual for Success and MoneyBall Medicine: Thriving in the New Data-Driven Healthcare Market

Harry_Glorikian_Moneyball_IVD_BioTech_Pharma_Summit_Profile_2

Title: The changing face of healthcare: dawn of individualized medicine

  • Shift to data driven and evidence based system to support value based health and healthcare decisions. Integration of multiplex diagnostics into development programs
  • Efficient and effective use of genetic and molecular characterization to shape the way medicine is practiced and the way drugs are approved
  • Greater integration of discovery, clinical trials, and ongoing clinical care to transform evidence generation for improved healthcare decisions